Regulation of PD-L1 Expression by YY1 in Cancer: Therapeutic Efficacy of Targeting YY1

被引:5
|
作者
Dillen, Ana [1 ]
Bui, Indy [1 ]
Jung, Megan [1 ]
Agioti, Stephanie [2 ]
Zaravinos, Apostolos [2 ,3 ]
Bonavida, Benjamin [1 ]
机构
[1] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, David Geffen Sch Med, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA
[2] Basic & Translat Canc Res Ctr BTCRC, Canc Genet Genom & Syst Biol Grp, CY-1516 Nicosia, Cyprus
[3] European Univ Cyprus, Sch Sci, Dept Life Sci, CY-2404 Nicosia, Cyprus
关键词
cancer; resistance; YY1; PD-L1; immunotherapy; T cells; inhibitors; overexpression; YIN-YANG; 1; NF-KAPPA-B; TUMOR-ASSOCIATED MACROPHAGES; TRANSCRIPTION FACTOR YY1; T-CELL EXHAUSTION; EPITHELIAL-MESENCHYMAL TRANSITION; CHECKPOINT BLOCKADE THERAPY; NITRIC-OXIDE; PROGRAMMED CELL-DEATH-1; INTERFERON PROMOTER;
D O I
10.3390/cancers16061237
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary We have recently witnessed several milestones in the treatment of various cancers with immunotherapy through modulating the activity of the immune system to suppress and destroy cancer cells. One main factor involved in the anti-cancer immune system is cytotoxic immune cells known as T cells. T cells can recognize pathogenic cancer cells and launch targeted destruction attacks. However, these T cells may become non-functional due to their close association with cancer cells within the tumor microenvironment. Cancer cell activity can ultimately suppress T-cell function. New approaches that prevent the inactivation of T cells by cancer cells would result in recovery of the T-cell functions, cancer regression, and overall survival. Targeting cancer cells specifically to prevent T-cell inactivation would result in tumor disappearance, inhibition of metastasis, and the reversal of resistance to therapy. Therefore, this proposed alternative approach is promising as it is applicable to numerous cancers, including those that are resistant to treatment.Abstract During the last decade, we have witnessed several milestones in the treatment of various resistant cancers including immunotherapeutic strategies that have proven to be superior to conventional treatment options, such as chemotherapy and radiation. This approach utilizes the host's immune response, which is triggered by cancer cells expressing tumor-associated antigens or neoantigens. The responsive immune cytotoxic CD8+ T cells specifically target and kill tumor cells, leading to tumor regression and prolongation of survival in some cancers; however, some cancers may exhibit resistance due to the inactivation of anti-tumor CD8+ T cells. One mechanism by which the anti-tumor CD8+ T cells become dysfunctional is through the activation of the inhibitory receptor programmed death-1 (PD-1) by the corresponding tumor cells (or other cells in the tumor microenvironment (TME)) that express the programmed death ligand-1 (PD-L1). Hence, blocking the PD-1/PD-L1 interaction via specific monoclonal antibodies (mAbs) restores the CD8+ T cells' functions, leading to tumor regression. Accordingly, the Food and Drug Administration (FDA) has approved several checkpoint antibodies which act as immune checkpoint inhibitors. Their clinical use in various resistant cancers, such as metastatic melanoma and non-small-cell lung cancer (NSCLC), has shown significant clinical responses. We have investigated an alternative approach to prevent the expression of PD-L1 on tumor cells, through targeting the oncogenic transcription factor Yin Yang 1 (YY1), a known factor overexpressed in many cancers. We report the regulation of PD-L1 by YY1 at the transcriptional, post-transcriptional, and post-translational levels, resulting in the restoration of CD8+ T cells' anti-tumor functions. We have performed bioinformatic analyses to further explore the relationship between both YY1 and PD-L1 in cancer and to corroborate these findings. In addition to its regulation of PD-L1, YY1 has several other anti-cancer activities, such as the regulation of proliferation and cell viability, invasion, epithelial-mesenchymal transition (EMT), metastasis, and chemo-immuno-resistance. Thus, targeting YY1 will have a multitude of anti-tumor activities resulting in a significant obliteration of cancer oncogenic activities. Various strategies are proposed to selectively target YY1 in human cancers and present a promising novel therapeutic approach for treating unresponsive cancer phenotypes. These findings underscore the distinct regulatory roles of YY1 and PD-L1 (CD274) in cancer progression and therapeutic response.
引用
收藏
页数:30
相关论文
共 50 条
  • [1] YY1 regulates cancer cell immune resistance by modulating PD-L1 expression
    Hays, Emily
    Bonavida, Benjamin
    DRUG RESISTANCE UPDATES, 2019, 43 : 10 - 28
  • [2] Therapeutic Implications of Targeting YY1 in Glioblastoma
    Navasardyan, Inesa
    Zaravinos, Apostolos
    Bonavida, Benjamin
    CANCERS, 2024, 16 (11)
  • [3] Expression of YY1 in Differentiated Thyroid Cancer
    Arribas, Jessica
    Castellvi, Josep
    Marcos, Ricard
    Zafon, Carles
    Velazquez, Antonia
    ENDOCRINE PATHOLOGY, 2015, 26 (02) : 111 - 118
  • [4] Expression of YY1 in Differentiated Thyroid Cancer
    Jéssica Arribas
    Josep Castellví
    Ricard Marcos
    Carles Zafón
    Antonia Velázquez
    Endocrine Pathology, 2015, 26 : 111 - 118
  • [5] Regulation of the Transcription Factor YY1 in Mitosis
    Rizkallah, Raed
    Alexander, Karen
    Kassarjian, Ari
    Hurt, Myra
    FASEB JOURNAL, 2009, 23
  • [6] YY1 EXPRESSION IN WILMS-' TUMOR
    Cabrera-Munoz, Lourdes
    Huerta-Yepez, Sara
    Juarez-Villegas, Luis E.
    Zapata-Tarres, Marta
    Sadowinski-Pine, Stanislaw
    LABORATORY INVESTIGATION, 2017, 97 : 465A - 465A
  • [7] YY1 EXPRESSION IN WILMS-' TUMOR
    Cabrera-Munoz, Lourdes
    Huerta-Yepez, Sara
    Juarez-Villegas, Luis E.
    Zapata-Tarres, Marta
    Sadowinski-Pine, Stanislaw
    MODERN PATHOLOGY, 2017, 30 : 465A - 465A
  • [8] Transcriptional regulation of POSTN gene expression by YY1 and BRCA1
    Falbo, L.
    Romeo, F.
    Di Sanzo, M.
    Misaggi, R.
    Cuda, G.
    Faniello, M. C.
    Quaresima, B.
    Costanzo, F.
    FEBS JOURNAL, 2011, 278 : 204 - 204
  • [9] Multifaceted regulation of hepatic lipid metabolism by YY1
    Pan, Gang
    Diamanti, Klev
    Cavalli, Marco
    Gutierrez, Ariadna Lara
    Komorowski, Jan
    Wadelius, Claes
    LIFE SCIENCE ALLIANCE, 2021, 4 (07)
  • [10] Regulation of transcription factor YY1 by acetylation and deacetylation
    Yao, YL
    Yang, WM
    Seto, E
    MOLECULAR AND CELLULAR BIOLOGY, 2001, 21 (17) : 5979 - 5991